The first descriptions of utilizing cut-off values with Ki-67 levels to make clinical decisions and to estimate prognosis were derived from Ki-67 measurements obtained from tumour samples in the IBCSG VIII and IX prospective clinical trials1,2,7,12,14,17,35. The gene discussed is MKI67; the disease is neoplasm.